ArticleChembiochem : a European journal of chemical biology2026
Computational Analysis of Chromophore-Controlled Photoactivation in Monofunctional Platinum(II)-BODIPY Conjugates for Dual Chemo-Photodynamic Therapy.
Article in Chembiochem : a European journal of chemical biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Platinum(II)-based photoactivatable anticancer agents that combine chemotherapy and photodynamic therapy (PDT) represent a promising strategy to overcome resistance and systemic toxicity of classical platinum drugs. Herein, we report a density functional theory (DFT) and time-dependent DFT investigation of dipicolylamine (dpa)-based monofunctional Pt(II) complexes conjugated to boron dipyrromethene (BODIPY) chromophores. Starting from two experimentally characterized systems, we designed new Pt-BODIPY architectures aimed at shifting light absorption into the therapeutic window (600-850 nm) while preserving platinum reactivity toward DNA. The results demonstrate that extension of π-conjugation and appropriate linker engineering effectively redshift the absorption maximum up to 661 nm without compromising capability of singlet oxygen generation. All conjugates exhibit triplet energies (1.03-1.57 eV) sufficient to sensitize molecular oxygen and calculated intersystem crossing (ISC) rates typical of chromophore-dominated systems, with limited spin-orbit coupling (SOC) enhancement from the Pt center. Mechanistic analysis of aquation and guanine coordination shows activation barriers and thermodynamics comparable to conventional Pt(II) drugs, indicating that chromophore conjugation does not hinder DNA platination. Overall, this study provides structure-property relationships and rational guidelines for the development of dual-action Pt-BODIPY chemo-photodynamic agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.